Pence charged with fronting coronavirus risk, Azar says he’s still in charge of taskforce

President Trump put Vice President Mike Pence in charge of the coronavirus epidemic during a press briefing Feb. 26, but HHS Secretary Alex Azar said he is still chairman of the press conference.

The administration recently asked for $2.5 billion in additional funding to mitigate the coronavirus, which has been called COVID-19 and has sickened thousands worldwide. The vast majority of the cases are confined to China, where the novel coronavirus originated, but cases have also spread to the U.S. Officials also believe a wider spread in the U.S. is “inevitable,” former director of the CDC Tom Friedman wrote in an editorial for CNN.

Trump noted that Pence would lead the response from the U.S. government to fight the coronavirus.

“I'm going to be putting our Vice President Mike Pence in charge, and Mike will be working with the professionals, doctors and everybody else that's working,” he said during the televised briefing.

Azar noted he did not feel replaced by Pence when asked by reporters.

The impact on financial markets due to fears and risks of the virus have been severe, with stocks plunging worldwide. Healthcare stocks in particular have been hard hit.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.